3 recruiting, 2 completed, 1 unknown. 6 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Recruiting 3, Completed 2, Unknown 1 |
| Phase 2 | 2 | Recruiting 2 |
Follow Solid Tumor: new trials by email Literature Review of Solid Tumor trials Research Report on Solid Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trop2-targeted immunoPET Imaging of Solid Tumors [68Ga]Ga-NOTA-T4, [68Ga]Ga-NOTA-RT4, [18F]F-RESCA-T4 - Solid Tumor, Solid Carcinoma | Phase 2 / Phase 3 | Recruiting | RenJi Hospital | 400 | 2024-12-23 | 2026-05-29 |
| To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer IAH0968, Trastuzumab Injection - Stomach Neoplasms, Solid Tumor | Phase 2 / Phase 3 | Recruiting | SUNHO(China)BioPharmaceutical CO., Ltd. | 574 | 2024-08-15 | 2026-06-05 |
| An Extension Study for Patients Previously Enrolled in Studies With Pelabresib Pelabresib, Ruxolitinib - Hematologic Malignancy, Solid Tumor | Phase 3 | Recruiting | Novartis Pharmaceuticals | 50 | 2024-08-13 | 2026-11-12 |
| An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study Onartuzumab, Bevacizumab, Erlotinib - Solid Tumor | Phase 3 | Completed | Hoffmann-La Roche | 12 | 2015-08-27 | 2019-07-23 |
| A Study to Assess the Efficacy and Safety of Eltrombopag as a Rescue of Isolated Chemotherapy-induced Thrombocytopenia Eltrombopag, Placebo - Solid Tumor | Phase 3 | Unknown | Chang Gung Memorial Hospital | 83 | 2014-03-01 | 2017-10-24 |
| Effectiveness of Antibiotic Prophylaxis for Totally Implantable Venous Access Device cefazolin Sodium, placebo - Solid Tumor | Phase 3 | Completed | Istanbul University | 150 | 2008-09-01 | 2010-06-02 |
Carcinoma, Transitional Cell (1) · Cholangiocarcinoma (1) · Endometrial Neoplasms (1) · Head and Neck Neoplasms (1) · Hematologic Neoplasms (1) · Infections (1) · Liver Neoplasms (1) · Lung Neoplasms (1) · Nasopharyngeal Neoplasms (1) · Ovarian Neoplasms (1) · Prostatic Neoplasms (1) · Stomach Neoplasms (1) · Thrombocytopenia (1) · Thyroid Neoplasms (1) · Urinary Bladder Neoplasms (1)
Neoplasms (3) · Neoplasms by Site (3) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Adenocarcinoma (1) · Adnexal Diseases (1) · Blood Platelet Disorders (1) · Carcinoma (1) · Cytopenia (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1)
Bevacizumab (1) · CPI-0610 (1) · Cefazolin (1) · Erlotinib Hydrochloride (1) · Trastuzumab (1) · eltrombopag (1) · onartuzumab (1) · ruxolitinib (1)
Chang Gung Memorial Hospital (1) · Hoffmann-La Roche (1) · Istanbul University (1) · Novartis Pharmaceuticals (1) · RenJi Hospital (1) · SUNHO(China)BioPharmaceutical CO., Ltd. (1)
China (2) · Italy (2) · Belgium (1) · France (1) · Japan (1) · Latvia (1) · Netherlands (1) · Russia (1) · Serbia (1) · South Africa (1) · Spain (1) · Taiwan (1) · Turkey (Türkiye) (1) · United Kingdom (1) · United States (1)
Hasan Karanlik, MD (1) · Hung-Hsueh Chou (1) · Jianjun Liu, Ph.D. & M.D. (1) · Weijun Wei, Ph.D. & M.D. (1)
2014 (1), 2023 (1)